Aim: The productivity of pharmaceutical research and development (R&D) investments is declining due to high failure rates in clinical research. Recently, the US Food and Drug Administration (FDA) acknowledged that adaptive designs can make drug development more efficient and less costly. Our...

The Korean government believes it can turn the country into one of the top 10 competitive economies by 2010. This volume offers an in-depth analysis of the Korean innovation system and shows how its science and technology policies actually work. As Korea's economy is now reaching the status of a...

During the 1990''s, the pharmaceutical R&D process has witnessed tremendous technological changes. The emergence of new tools like ''combinatorial chemistry'', ''high throughput screening'' and the in-creasing use of computer-aided in silico experiments has led to significant improvements of...

During the past 20 years, the world pharmaceutical industry has experienced a dramatic increase in R&D intensity. We apply and extend a model developed by Grabowski and Vernon (2000) with a pooled data sample of the 15 publicly listed Japanese drug firms for the period 1987 to 1998. As in the...

Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...

Aim: The productivity of pharmaceutical research and development (R&D) investments is declining due to high failure rates in clinical research. Recently, the US Food and Drug Administration (FDA) acknowledged that adaptive designs can make drug development more efficient and less costly. Our...